Annual EBITDA
$138.29 M
+$28.64 M+26.12%
December 31, 2024
Summary
- As of March 4, 2025, CORT annual EBITDA is $138.29 million, with the most recent change of +$28.64 million (+26.12%) on December 31, 2024.
- During the last 3 years, CORT annual EBITDA has risen by +$10.33 million (+8.08%).
- CORT annual EBITDA is now at all-time high.
Performance
CORT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$25.72 M
-$21.38 M-45.39%
December 31, 2024
Summary
- As of March 4, 2025, CORT quarterly EBITDA is $25.72 million, with the most recent change of -$21.38 million (-45.39%) on December 31, 2024.
- Over the past year, CORT quarterly EBITDA has dropped by -$6.22 million (-19.47%).
- CORT quarterly EBITDA is now -45.39% below its all-time high of $47.10 million, reached on September 30, 2024.
Performance
CORT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$138.29 M
-$6.22 M-4.30%
December 31, 2024
Summary
- As of March 4, 2025, CORT TTM EBITDA is $138.29 million, with the most recent change of -$6.22 million (-4.30%) on December 31, 2024.
- Over the past year, CORT TTM EBITDA has increased by +$28.64 million (+26.12%).
- CORT TTM EBITDA is now -4.30% below its all-time high of $144.51 million, reached on September 30, 2024.
Performance
CORT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CORT EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +26.1% | -19.5% | +26.1% |
3 y3 years | +8.1% | -19.5% | +26.1% |
5 y5 years | +21.5% | -19.5% | +26.1% |
CORT EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +26.1% | -45.4% | +63.7% | -4.3% | +36.3% |
5 y | 5-year | at high | +26.1% | -45.4% | +63.7% | -4.3% | +36.3% |
alltime | all time | at high | +433.9% | -45.4% | +300.5% | -4.3% | +419.2% |
Corcept Therapeutics Incorporated EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | $138.29 M(+26.1%) | $25.72 M(-45.4%) | $138.29 M(-4.3%) |
Sep 2024 | - | $47.10 M(+31.6%) | $144.51 M(+12.1%) |
Jun 2024 | - | $35.79 M(+20.6%) | $128.88 M(+4.3%) |
Mar 2024 | - | $29.68 M(-7.1%) | $123.61 M(+12.7%) |
Dec 2023 | $109.64 M(-5.5%) | $31.94 M(+1.5%) | $109.64 M(+8.1%) |
Sep 2023 | - | $31.47 M(+3.1%) | $101.43 M(-1.2%) |
Jun 2023 | - | $30.52 M(+94.3%) | $102.65 M(-1.5%) |
Mar 2023 | - | $15.71 M(-33.8%) | $104.22 M(-10.2%) |
Dec 2022 | $116.08 M(-9.3%) | $23.72 M(-27.4%) | $116.08 M(-10.9%) |
Sep 2022 | - | $32.69 M(+1.8%) | $130.23 M(-3.2%) |
Jun 2022 | - | $32.10 M(+16.4%) | $134.54 M(-0.4%) |
Mar 2022 | - | $27.57 M(-27.2%) | $135.14 M(+5.6%) |
Dec 2021 | $127.95 M(-1.9%) | $37.87 M(+2.3%) | $127.95 M(+5.6%) |
Sep 2021 | - | $37.00 M(+13.2%) | $121.16 M(+10.7%) |
Jun 2021 | - | $32.70 M(+60.4%) | $109.44 M(-2.7%) |
Mar 2021 | - | $20.38 M(-34.4%) | $112.51 M(-13.7%) |
Dec 2020 | $130.44 M(+14.6%) | $31.07 M(+22.9%) | $130.44 M(-3.3%) |
Sep 2020 | - | $25.28 M(-29.3%) | $134.94 M(-5.8%) |
Jun 2020 | - | $35.77 M(-6.6%) | $143.24 M(+8.0%) |
Mar 2020 | - | $38.31 M(+7.7%) | $132.63 M(+16.6%) |
Dec 2019 | $113.78 M(+26.8%) | $35.58 M(+6.0%) | $113.78 M(+10.3%) |
Sep 2019 | - | $33.58 M(+33.5%) | $103.17 M(+11.4%) |
Jun 2019 | - | $25.16 M(+29.3%) | $92.62 M(+5.1%) |
Mar 2019 | - | $19.46 M(-22.0%) | $88.15 M(-1.8%) |
Dec 2018 | $89.73 M(+69.4%) | $24.97 M(+8.4%) | $89.73 M(+3.7%) |
Sep 2018 | - | $23.03 M(+11.3%) | $86.51 M(+12.1%) |
Jun 2018 | - | $20.69 M(-1.7%) | $77.14 M(+11.4%) |
Mar 2018 | - | $21.04 M(-3.2%) | $69.25 M(+30.8%) |
Dec 2017 | $52.96 M(+415.9%) | $21.75 M(+59.2%) | $52.96 M(+46.1%) |
Sep 2017 | - | $13.66 M(+6.7%) | $36.24 M(+41.2%) |
Jun 2017 | - | $12.80 M(+169.4%) | $25.67 M(+78.3%) |
Mar 2017 | - | $4.75 M(-5.4%) | $14.40 M(+40.3%) |
Dec 2016 | $10.27 M(-412.2%) | $5.02 M(+62.4%) | $10.27 M(+48.3%) |
Sep 2016 | - | $3.09 M(+101.9%) | $6.92 M(+74.7%) |
Jun 2016 | - | $1.53 M(+147.5%) | $3.96 M(+199.9%) |
Mar 2016 | - | $619.00 K(-63.1%) | $1.32 M(-140.2%) |
Dec 2015 | -$3.29 M(-88.0%) | $1.68 M(+1172.0%) | -$3.29 M(-58.9%) |
Sep 2015 | - | $132.00 K(-111.9%) | -$8.01 M(-39.4%) |
Jun 2015 | - | -$1.11 M(-72.2%) | -$13.20 M(-29.2%) |
Mar 2015 | - | -$3.99 M(+31.3%) | -$18.64 M(-32.2%) |
Dec 2014 | -$27.48 M(-33.7%) | -$3.04 M(-40.0%) | -$27.48 M(-20.2%) |
Sep 2014 | - | -$5.06 M(-22.6%) | -$34.45 M(-11.9%) |
Jun 2014 | - | -$6.54 M(-49.0%) | -$39.10 M(-9.7%) |
Mar 2014 | - | -$12.83 M(+28.2%) | -$43.32 M(+4.6%) |
Dec 2013 | -$41.42 M | -$10.01 M(+3.0%) | -$41.42 M(+0.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2013 | - | -$9.72 M(-9.7%) | -$41.38 M(+5.2%) |
Jun 2013 | - | -$10.76 M(-1.5%) | -$39.33 M(+8.8%) |
Mar 2013 | - | -$10.93 M(+9.7%) | -$36.15 M(-0.3%) |
Dec 2012 | -$36.24 M(+12.1%) | -$9.97 M(+30.0%) | -$36.24 M(+0.1%) |
Sep 2012 | - | -$7.67 M(+1.0%) | -$36.20 M(+3.5%) |
Jun 2012 | - | -$7.59 M(-31.2%) | -$34.97 M(-3.5%) |
Mar 2012 | - | -$11.03 M(+11.1%) | -$36.26 M(+12.2%) |
Dec 2011 | -$32.33 M(+24.6%) | -$9.92 M(+54.2%) | -$32.33 M(+12.5%) |
Sep 2011 | - | -$6.44 M(-27.4%) | -$28.73 M(-2.3%) |
Jun 2011 | - | -$8.87 M(+25.0%) | -$29.40 M(+9.0%) |
Mar 2011 | - | -$7.10 M(+12.2%) | -$26.97 M(+4.0%) |
Dec 2010 | -$25.93 M(+28.1%) | -$6.33 M(-10.9%) | -$25.94 M(+4.7%) |
Sep 2010 | - | -$7.10 M(+10.3%) | -$24.77 M(+10.9%) |
Jun 2010 | - | -$6.44 M(+6.3%) | -$22.33 M(+7.5%) |
Mar 2010 | - | -$6.06 M(+17.4%) | -$20.77 M(+2.6%) |
Dec 2009 | -$20.24 M(+2.9%) | -$5.16 M(+10.6%) | -$20.24 M(-4.0%) |
Sep 2009 | - | -$4.67 M(-4.4%) | -$21.09 M(-1.1%) |
Jun 2009 | - | -$4.88 M(-11.8%) | -$21.32 M(+0.9%) |
Mar 2009 | - | -$5.53 M(-8.0%) | -$21.13 M(+7.4%) |
Dec 2008 | -$19.68 M(+60.9%) | -$6.01 M(+22.8%) | -$19.68 M(+8.8%) |
Sep 2008 | - | -$4.90 M(+4.6%) | -$18.08 M(+7.7%) |
Jun 2008 | - | -$4.68 M(+14.8%) | -$16.79 M(+22.7%) |
Mar 2008 | - | -$4.08 M(-7.6%) | -$13.69 M(+11.9%) |
Dec 2007 | -$12.23 M(-52.2%) | -$4.42 M(+22.2%) | -$12.23 M(+3.6%) |
Sep 2007 | - | -$3.61 M(+129.3%) | -$11.80 M(-19.9%) |
Jun 2007 | - | -$1.58 M(-40.0%) | -$14.73 M(-30.6%) |
Mar 2007 | - | -$2.63 M(-34.2%) | -$21.22 M(-17.0%) |
Dec 2006 | -$25.57 M(+25.0%) | -$3.99 M(-39.1%) | -$25.57 M(-3.1%) |
Sep 2006 | - | -$6.55 M(-18.8%) | -$26.39 M(+4.2%) |
Jun 2006 | - | -$8.06 M(+15.5%) | -$25.32 M(+17.0%) |
Mar 2006 | - | -$6.98 M(+45.2%) | -$21.65 M(+7.4%) |
Dec 2005 | -$20.45 M(+41.7%) | -$4.80 M(-12.3%) | -$20.15 M(-1.8%) |
Sep 2005 | - | -$5.48 M(+25.0%) | -$20.51 M(+7.4%) |
Jun 2005 | - | -$4.39 M(-20.0%) | -$19.09 M(+6.9%) |
Mar 2005 | - | -$5.48 M(+6.1%) | -$17.86 M(+23.7%) |
Dec 2004 | -$14.44 M(+45.1%) | -$5.17 M(+27.2%) | -$14.44 M(+27.9%) |
Sep 2004 | - | -$4.06 M(+28.7%) | -$11.28 M(+20.3%) |
Jun 2004 | - | -$3.15 M(+53.5%) | -$9.38 M(+2.6%) |
Mar 2004 | - | -$2.06 M(+2.0%) | -$9.14 M(-8.1%) |
Dec 2003 | -$9.95 M(-47.1%) | -$2.01 M(-6.6%) | -$9.95 M(+25.4%) |
Sep 2003 | - | -$2.16 M(-26.1%) | -$7.93 M(+37.3%) |
Jun 2003 | - | -$2.92 M(+2.0%) | -$5.78 M(+102.0%) |
Mar 2003 | - | -$2.86 M | -$2.86 M |
Dec 2002 | -$18.80 M(+134.8%) | - | - |
Dec 2001 | -$8.01 M | - | - |
FAQ
- What is Corcept Therapeutics Incorporated annual EBITDA?
- What is the all time high annual EBITDA for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated annual EBITDA year-on-year change?
- What is Corcept Therapeutics Incorporated quarterly EBITDA?
- What is the all time high quarterly EBITDA for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated quarterly EBITDA year-on-year change?
- What is Corcept Therapeutics Incorporated TTM EBITDA?
- What is the all time high TTM EBITDA for Corcept Therapeutics Incorporated?
- What is Corcept Therapeutics Incorporated TTM EBITDA year-on-year change?
What is Corcept Therapeutics Incorporated annual EBITDA?
The current annual EBITDA of CORT is $138.29 M
What is the all time high annual EBITDA for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high annual EBITDA is $138.29 M
What is Corcept Therapeutics Incorporated annual EBITDA year-on-year change?
Over the past year, CORT annual EBITDA has changed by +$28.64 M (+26.12%)
What is Corcept Therapeutics Incorporated quarterly EBITDA?
The current quarterly EBITDA of CORT is $25.72 M
What is the all time high quarterly EBITDA for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high quarterly EBITDA is $47.10 M
What is Corcept Therapeutics Incorporated quarterly EBITDA year-on-year change?
Over the past year, CORT quarterly EBITDA has changed by -$6.22 M (-19.47%)
What is Corcept Therapeutics Incorporated TTM EBITDA?
The current TTM EBITDA of CORT is $138.29 M
What is the all time high TTM EBITDA for Corcept Therapeutics Incorporated?
Corcept Therapeutics Incorporated all-time high TTM EBITDA is $144.51 M
What is Corcept Therapeutics Incorporated TTM EBITDA year-on-year change?
Over the past year, CORT TTM EBITDA has changed by +$28.64 M (+26.12%)